Novasep opens viral vector fill-finish facility

The Senefill facility in Belgium is part of Novasep's flagship centre for the manufacturing of commercial viral vectors

Video showing the process used in the Senefill fill-finish facility

Novasep has launched Senefill, a unit dedicated to fill-finish aseptic commercial operations, in Seneffe, Belgium. With a full state-of-the-art facility, Senefill will be commissionable 1 October and will provide standalone fill-finish services as well as integrated drug product manufacturing, from formulation to packaging.

Senefill is an 1800 sqm (19,000 sqft) unit, with a 400 sqm (4,300 sqft) area dedicated to the filling of a wide range of biological products: viral vectors, viruses, monoclonal antibodies and other biologics. These operations will support key biopharmaceutical markets for Novasep and its clients: cell and gene therapies, oncology, vaccination and other innovative therapies.

This fill-finish unit features semi-automatic and automatic liquid filling machines under isolator and can deliver up to 10,000 vials per session, with 2 to 3 sessions per week. Quality Control and visual inspections will be carried out by highly qualified technicians.

Senefill is part of Senrise-IV, Novasep's flagship for the manufacturing of commercial viral vectors. This configuration makes it possible to have both production and fill-finish operations on the same site helping provide reliability and performance of manufacturing services to secure reliable supply.

Senefill also provides meeting rooms and visit zones from where visitors can observe fill-finish operations.

Pierre Lunel, Director of the Belgian site, said that a team of 24 people will operate this unit when at full strength.

"Senefill is a major step for Novasep to achieve its growth strategy, Rise-2. This unit strongly distinguishes Novasep from its competitors in the market for viral vector drug product manufacturing services. It was crucial for us to be able to meet the growing needs of our clients for targeted and innovative therapies and address patients' needs," states Michel Spagnol, Chairman and CEO of Novasep.

Companies